Aignostics secures $34 million Series B to improve precision medicine with AI

Investments will support new product offerings, US expansion, and development of pathology foundation models

05-Nov-2024 - Aignostics, a global artificial intelligence (AI) company that turns complex multi-modal pathology data into transformative insights, announced that it has raised $34 million in Series B financing. This additional funding will be used to build new product offerings for biopharmaceutical clients, ...

Hong Kong firm invests in Jena-based Oncgnostics GmbH

12-Sep-2023 - The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a seven-digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer diagnostic Gyntect for the reliable detection of cervical cancer. Since 2022, this test has also been ...

Precision diagnostics to immune medicine using AI-assisted analysis of single-cell blood data

hema.to raises €3.6M

20-Jul-2023 - hema.to’s mission is to make the clinical analysis of blood data — called cytometry — automated and fully objective to enable personalization of treatment to every person’s unique immune system. Currently, even for skilled laboratory personnel, cytometry analysis is a laborious process that has a ...

Diagnosing cancer in minutes

Identify tumour margins directly in the surgery room: Refined Laser Systems raises €2.7m

30-Jan-2023 - Refined Laser Systems, a dynamic biophotonics company specialised in pioneering laser systems for SRS-microscopy and quantum technology, today announces a Seed funding round of €2.7 million led by High-Tech Gründerfonds and APEX Ventures, along with NRW.BANK, Onsight Ventures and Papst Venture ...

Aignostics Raises €14m Series A to Advance AI-powered Pathology

Spin-off from Charité developing sophisticated AI models to improve understanding, diagnosis and treatment of complex diseases

19-Sep-2022 - Aignostics, a spin-off from Charité – Universitätsmedizin Berlin, developing novel digital pathology solutions with “Explainable AI” for pharmaceutical research and diagnostics, today announced the closing of an oversubscribed €14m Series A financing round. Wellington Partners led the round, ...

C-mo Medical Solutions raises €4.1 million aiming to transform cough monitoring

14-Sep-2022 - C-mo Medical Solutions is an award-winning start-up that is unravelling the potential of assessing cough towards improved diagnosis, treatment courses and disease management. The company has now raised 4.1€Mn in a seed round led by Boehringer Ingelheim Venture Fund. This investment will allow the ...

Deep learning for faster, more accurate and safer MRI analysis

International pool invests ~ 2 Mio € in medicine start-up mediaire

17-Dec-2020 - HTGF, primeCROWD and LIFTT are part of an international round for the development of “Deep learning diagnostic” which allows faster, more accurate and safer MRI analysis. Expansion into European markets will start in 2021 accompanied by a significant expansion of product portfolio mediaire, the ...

Start-up miRdetect receives seed financing

Consortium invests seven-digit amount in serum marker for testicular cancer detection

03-May-2019 - Together with BBM and a private investor, High-Tech Gründerfonds (HTGF) is investing a seven-figure sum in the start-up company miRdetect located in Bremen, and founded in 2016. The company founders Meike Spiekermann and Dr. Nina Winter were able to convince the investors with their novel and ...

neotiv secures seed funding from High-Tech Gründerfonds

17-Jan-2018 - From basic research straight to a digital medical product: this vision has been turned into reality by neotiv. The team headed by Chief Executive Officer Dr. Chris Rehse and dementia researcher Prof. Emrah Düzel develops user-friendly apps that are able to measure the psychological effects of ...

Innovationsstarter Fonds Hamburg and High-Tech Gründerfonds are investing together in KSK Diagnostics GmbH

Development of molecular point-of-care diagnostic tests

26-Apr-2017 - KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the time before therapy is started. A financing round has now been ...